vTv Therapeutics Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über vTv Therapeutics Inc Unternehmen

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

vTv Therapeutics Inc Informationen



BörsenkürzelVTVT

Name des UnternehmensvTv Therapeutics Inc

IPO-datumJul 30, 2015

CEOSekhri (Paul Jai)

Anzahl der mitarbeiter23

WertpapierartOrdinary Share

GeschäftsjahresendeJul 30

Addresse3980 Premier Dr

StadtHIGH POINT

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl27265

Telefon13368410300

Websitehttps://vtvtherapeutics.com/

BörsenkürzelVTVT

IPO-datumJul 30, 2015

CEOSekhri (Paul Jai)

Führungskräfte von vTv Therapeutics Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-24062.00%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

+2146.00%

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

+1833.00%

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Mr. Burns Mcclellan

Investor Relations

--

Dr. Srinivas Akkaraju, M.D., Ph.D.

Independent Director

--

-2251.00%

Mr. Daniel (Dan) Spiegelman

Director

--

Dr. Michael Tung, M.D.

Executive Vice President, Chief Financial Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Mr. Paul Jai Sekhri

Chairman of the Board, President, Chief Executive Officer

5.00K

-24062.00%

Dr. Anne M. Phillips, M.D.

Independent Director

2.15K

+2146.00%

Dr. Raymond Cheong, M.D., Ph.D.

Independent Director

1.83K

+1833.00%

Mr. Richard S. (Rich) Nelson

Executive Vice President - Corporate Development, Director

--

Mr. Fahed Al Marzooqi, M.D.

Independent Director

--

Mr. Burns Mcclellan

Investor Relations

--

Umsatzaufteilung

FY2023

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach RegionUSD

Name

Umsatz

Anteil

United States

0.00

0.00%

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Fri, Feb 6

Aktionäre

Aktionärstypen

Aktionäre

Anteil

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

Andere

54.33%

Aktionäre

Anteil

MacAndrews & Forbes Holdings, Inc.

23.18%

Samsara BioCapital, LLC

7.58%

Trails Edge Capital Partners LP

5.87%

Fidelity Management & Research Company LLC

4.90%

Invus Public Equities Advisors, LLC

4.14%

Andere

54.33%

Aktionärstypen

Aktionäre

Anteil

Holding Company

23.18%

Investment Advisor

17.37%

Venture Capital

7.58%

Hedge Fund

4.34%

Investment Advisor/Hedge Fund

0.75%

Individual Investor

0.42%

Andere

46.35%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

44

1.18M

30.04%

+255.03K

2025Q3

47

1.15M

29.13%

+562.26K

2025Q2

54

1.51M

57.66%

-17.51K

2025Q1

53

1.53M

60.03%

+1.63K

2024Q4

55

1.51M

61.92%

-7.51K

2024Q3

55

1.49M

61.31%

+181.69K

2024Q2

53

1.29M

53.13%

+308.00

2024Q1

64

1.68M

72.07%

+129.32K

2023Q4

64

1.40M

68.78%

-52.49K

2023Q3

72

1.41M

69.35%

-49.61K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

MacAndrews & Forbes Holdings, Inc.

912.98K

23.18%

--

Apr 01, 2025

Samsara BioCapital, LLC

298.50K

7.58%

-75.97K

-20.29%

Dec 08, 2025

Trails Edge Capital Partners LP

231.00K

5.87%

+231.00K

--

Aug 29, 2025

Fidelity Management & Research Company LLC

192.89K

4.9%

+14.69K

+8.24%

Sep 30, 2025

Invus Public Equities Advisors, LLC

163.00K

4.14%

--

Sep 30, 2025

Baker Bros. Advisors LP

148.31K

3.77%

+51.00K

+52.41%

Sep 30, 2025

The Vanguard Group, Inc.

46.99K

1.19%

+3.81K

+8.84%

Sep 30, 2025

Geode Capital Management, L.L.C.

15.30K

0.39%

+2.43K

+18.90%

Sep 30, 2025

Northern Trust Investments, Inc.

14.07K

0.36%

-1.22K

-7.95%

Sep 30, 2025

Millennium Management LLC

12.94K

0.33%

-2.11K

-14.01%

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0.01%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Micro-Cap ETF

Anteil0.01%

iShares Core S&P Total U.S. Stock Market ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Datum

Ex-Dividendentag

Art

Verhältnis

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1

Nov 15, 2023

Merger

40→1